CoChat

5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy

Open access
Howley, Richard, Chandratre, Sharayu, Chen, Bin · 2023 · Bioengineering

The DOI matches its Crossref record; 170 of the 180 references it cites were found in a registry or an index; 75 of the 205 sources its claims cite were checked for support.

Abstract

5-Aminolevulinic acid (ALA) is a naturally occurring amino acid synthesized in all nucleated mammalian cells. As a porphyrin precursor, ALA is metabolized in the heme biosynthetic pathway to produce protoporphyrin IX (PpIX), a fluorophore and photosensitizing agent. ALA administered exogenously bypasses the rate-limit step in the pathway, resulting in PpIX accumulation in tumor tissues. Such tumor-selective PpIX disposition following ALA administration has been exploited for tumor fluorescence diagnosis and photodynamic therapy (PDT) with much success. Five ALA-based drugs have now received worldwide approval and are being used for managing very common human (pre)cancerous diseases such as actinic keratosis and basal cell carcinoma or guiding the surgery of bladder cancer and high-grade gliomas, making it the most successful drug discovery and development endeavor in PDT and photodiagnosis. The potential of ALA-induced PpIX as a fluorescent theranostic agent is, however, yet to be fully fulfilled. In this review, we would like to describe the heme biosynthesis pathway in which PpIX is produced from ALA and its derivatives, summarize current clinical applications of ALA-based drugs, and discuss strategies for enhancing ALA-induced PpIX fluorescence and PDT response. Our goal is two-fold: to highlight the successes of ALA-based drugs in clinical practice, and to stimulate the multidisciplinary collaboration that has brought the current success and will continue to usher in more landmark advances.

Overview

CoChat Summary

## TL;DR

This review explains how 5-aminolevulinic acid (ALA) is converted to protoporphyrin IX (PpIX), and how that PpIX enables both fluorescence-guided tumor diagnosis and photodynamic therapy (PDT). It argues that ALA-based drugs are already highly successful in actinic keratosis, basal cell carcinoma, bladder cancer, and high-grade gliomas, while additional protocol, device, and pathway-targeting refinements may further improve outcomes.

## Key findings

  • Five ALA-based drugs had received worldwide approval by the time of the review, and the paper identifies ALA-based therapy as “the most successful drug discovery and development endeavor in PDT and photodiagnosis.”
  • For high-grade glioma, the paper reports that a randomized phase III trial found fluorescence-guided resection achieved more gross total resection than white-light surgery: 65% vs 36%, with higher 6-month progression-free survival (41% vs 21%).
  • For bladder cancer, the paper reports that in 68 patients, ALA-induced fluorescence had 100% sensitivity and 68.5% specificity for tumor detection, and that fluorescence cystoscopy revealed 26 cancerous or precancerous lesions out of 299 biopsies that white light would have missed.
  • For actinic keratosis and superficial BCC, the paper reports multiple clinical results, including 72% complete response at 12 weeks for head actinic keratosis with ALA + blue light, up to 91% complete response for AK and 97% for BCC with MAL-PDT, and about 85% lesion clearance with BF-200 ALA and a simulated daylight system.
  • The review highlights enhancement strategies that can raise PpIX fluorescence or PDT response, including optimizing dose/timing, fractionated illumination, daylight or simulated daylight systems, iron chelation, FECH inhibition, ABCG2 inhibition, pro-survival pathway inhibition, and immune checkpoint blockade.

## Methods

  • Narrative review of the ALA/PpIX heme biosynthesis pathway, therapeutic PDT mechanisms, intraoperative fluorescence imaging, and strategies to enhance ALA-PpIX fluorescence and ALA-PDT response.
  • Uses published clinical trials, randomized trials, multicenter studies, and preclinical cell/animal studies as the evidence base; no new original patient cohort is reported in the paper.
  • Main analysis is qualitative synthesis, organizing findings by mechanism and application area (actinic keratosis, BCC, bladder cancer, glioma), and comparing protocols, devices, and combination strategies.

## Limitations

  • The paper states that the potential of ALA-induced PpIX as a fluorescent theranostic agent is “yet to be fully fulfilled.”
  • It explicitly notes that whether targeting PpIX bioconversion and efflux will produce clinical benefit “remains to be seen,” and that clinical trials are needed to test whether combined fluorescence-guided surgery plus PDT improves survival beyond current standard practice.
  • Evident from the text: much of the enhancement evidence comes from in vitro or animal studies, and several proposed inhibitors or protocol refinements are not yet clinically validated or are not available for clinical use.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/bioengineering10040496

Cites

170 of 170 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 ALA-mediated PpIX biosynthesis in the heme biosynthesis pathway. ALA administered exogenously is metabolized in the heme biosynthesis pathway, which is composed of four enzymes in the cytoplasm and four enzymes in the mitochondrion, to produce PpIX with red fluorescence and photosensitizing activity. PpIX can be converted to heme with no fluorescence and photosensitizing property or effluxed out via primarily ABCG2 transporter.
Figure 1 ALA-mediated PpIX biosynthesis in the heme biosynthesis pathway. ALA administered exogenously is metabolized in the heme biosynthesis pathway, which is composed of four enzymes in the cytoplasm and four enzymes in the mitochondrion, to produce PpIX with red fluorescence and photosensitizing activity. PpIX can be converted to heme with no fluorescence and photosensitizing property or effluxed out via primarily ABCG2 transporter.CC BY · PubMed Central
Figure 2 Pharmacological inhibition of PpIX-reducing biological processes for the enhancement of ALA-PpIX fluorescence and PDT. PpIX synthesized in mitochondria can be converted to heme by FECH (using Fe2+ as another substrate) and effluxed by ABCG2 transporter. Inhibition of these two predominant PpIX-reducing biological processes with chemical inhibitors enhances ALA-induced PpIX.
Figure 2 Pharmacological inhibition of PpIX-reducing biological processes for the enhancement of ALA-PpIX fluorescence and PDT. PpIX synthesized in mitochondria can be converted to heme by FECH (using Fe2+ as another substrate) and effluxed by ABCG2 transporter. Inhibition of these two predominant PpIX-reducing biological processes with chemical inhibitors enhances ALA-induced PpIX.CC BY · PubMed Central
Figure 3 Therapeutic enhancement of ALA and its derivative drugs for PDT, fluorescence tumor detection, and resection. All ALA-based drugs are prodrugs and need to be metabolized in the heme biosynthesis pathway to produce the active drug PpIX, a fluorophore and photosensitizer. PpIX can be bioconverted to heme (with no fluorescent and photosensitizing properties) and/or effluxed out of the cell, reducing intracellular PpIX tumor accumulation. Various strategies (shown in blue) have been demonstrated to enhance the therapeutic outcomes of ALA-based drugs. Current efforts are being undertaken to combine tumor diagnostic and therapeutic capabilities of ALA-derived PpIX for theranostic applications.
Figure 3 Therapeutic enhancement of ALA and its derivative drugs for PDT, fluorescence tumor detection, and resection. All ALA-based drugs are prodrugs and need to be metabolized in the heme biosynthesis pathway to produce the active drug PpIX, a fluorophore and photosensitizer. PpIX can be bioconverted to heme (with no fluorescent and photosensitizing properties) and/or effluxed out of the cell, reducing intracellular PpIX tumor accumulation. Various strategies (shown in blue) have been demonstrated to enhance the therapeutic outcomes of ALA-based drugs. Current efforts are being undertaken to combine tumor diagnostic and therapeutic capabilities of ALA-derived PpIX for theranostic applications.CC BY · PubMed Central

Verification

Claims the paper makes

49 Valid · 5 Not valid · 87 Not checked · 18 Own results and interpretations

94 more claims · 29 with their cited sources checked

Create a free account to see all 159 claims and to verify the 29 references still open.

See all claims — free account
  • Probably not a substantial claim. 8
  • It may state two separate claims as one. 56

Create a free account to see these claims.

Citations

Cites

Cited by

See all 33

Metadata

Authors
Howley, R., Chandratre, S., & Chen, B.
Affiliations
Saint Joseph's University (US)
Corresponding author
Chen, Bin
Venue
Bioengineering
Publisher
MDPI AG
Published
2023-04-21
Volume
10
Issue
4
Pages
496
ISSN
2306-5354 (ISSN-L)
OpenAlex
W4366775638
Cited by
33
References
180
Citations by year
2026: 8 · 2025: 6 · 2024: 15 · 2023: 3
FWCI
5.28
Type
journal article
Language
en
Open access
Locations
  • Bioengineering (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
NIH (R15CA268200)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Materials Science › Materials Chemistry › Porphyrin and Phthalocyanine Chemistry
Keywords
5-aminolevulinic acid, protoporphyrin IX, heme biosynthesis, photodynamic therapy, theranostics, photosensitizers, actinic keratosis, basal cell carcinoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.